Skip to main content

Advertisement

Fig. 3 | Journal of Hematology & Oncology

Fig. 3

From: Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients

Fig. 3

Pharmacodynamic readouts of JS001. a PD-1 receptor occupancy (RO) was determined as the percentage of receptor bound JS001 to total PD-1 on activated lymphocytes (CD3+ CD45RA−) from the peripheral blood by flow cytometry analysis. RO of responders (CR + PR + SD) and non-responders (PD) are shown. b The frequency of activated CD8+ T cells (CD3+ CD8+ CD45RA−) over time are shown in clinical responders and non-responders

Back to article page